A Phase 1 interventional study of HMPL-306 in Isocitrate Dehydrogenase Gene Mutation, sponsored by Hutchmed. Terminated at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Hutchmed · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies in Leukemia, Myeloid, Acute with a site in Spain — 35 open to participants now, 62 under way, 22 of them phase 3. Leukemia, Myeloid, Acute · Spain.
Among the 200 studies in Leukemia, Myeloid, Acute with a site in Spain, this one is the 148th largest by enrollment of the 189 interventional ones that give a count, is one of 21 that started in 2021, is one of 46 in phase 1, and was the 141st registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →35 of the 200 studies in Leukemia, Myeloid, Acute with a site in Spain are open now. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Spain
Ages 18+
AbbVie · Sites in Spain, United States, Austria and 4 more countries
Ages 18+
PETHEMA Foundation · Sites in Spain, Portugal
Ages 18+
Stichting Hemato-Oncologie voor Volwassenen Nederland · Sites in Spain, United States, Australia and 10 more countries
Ages 18+
Genmab · Sites in Spain, Denmark, Italy
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 88 · Phase 2 80 · Phase 3 61 · Phase 4 5
First in 1998; this study’s year is marked. 21 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 120 across the 189 interventional studies, 600 across the 11 observational. Of the 133 that completed or were terminated, 71 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
148 of 200 have an industry lead sponsor. The 10 most frequent:
This study is registered under Hutchmed, one of the names counted as HUTCHMED. Under that name alone:
Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
HUTCHMED has 4 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
20 of the studies in Leukemia, Myeloid, Acute with a site in Spain that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03839771Phase 3Stichting Hemato-Oncologie voor Volwassenen NederlandA Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | 2027-04-17 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 200 studies in Leukemia, Myeloid, Acute with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
HMPL-306 is a dual IDH1/2 inhibitor
This is a phase 1, open-label, multicenter, single-arm study to evaluate safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 administered orally in treatment of subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations (or co-mutations).
The study consists of 2 parts: a dose-escalation part (Part 1) and a dose-expansion part (Part 2). The dose-escalation part will determine the MTD/R2PD. The dose-expansion part will administer the MTD/RP2D to subjects with mIDH-positive AML
Key Inclusion Criteria:
Subjects may be enrolled in this study only if they satisfy all the following criteria (NOTE: This is not an exhaustive list):
Part 1:
Part 2:
Patients with AML must not have standard therapeutic options available (including IDH inhibitors where approved) and have the following:
Key Exclusion Criteria:
Subjects are not eligible for enrollment into this study if they meet any of the following criteria (NOTE: This is not an exhaustive list):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will be administered HMPL-306 orally QD
Drug: HMPL-306
Administered orally QD in a 28-day continuous dosing treatment cycle
Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of HMPL-306
RP2D determination took the following criteria under consideration: determination of maximum tolerated dose (MTD) achieved during the dose escalation part and assessment of safety, PK and pharmacodynamics (PD).
Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
Dose Escalation Part: Number of Patients With Dose-Limiting Toxicities (DLTs)
DLT was defined as occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless clearly unrelated to the study drug as per investigator's discretion: nonhematologic toxicity: TEAEs of Grade \>=4, Grade \>=3 with the exception of those that resolved within 72 hours (h) of onset; hematologic toxicity with the exception of neutropenia or thrombocytopenia that occurred with active leukemic disease: Grade 3 or 4 neutropenia lasting more than 7 days, Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or any requirement for platelets (PLT) transfusion, Grade 3 or greater febrile neutropenia defined as absolute neutrophil count (ANC) 1000 per cubic millimeter with a single temperature of \>38.3 degree Celsius (°C) or a sustained temperature of \>=38°C for more than 1 h; any TEAE requiring a dose delay of \>=14 days or cases of confirmed Hy's law.
Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)
AE:unfavorable and unintended sign,symptom or disease temporally associated with use of study drug or other protocol-imposed intervention, whether or not considered related to study drug. SAE:AE that resulted in death,life-threatening AE,inpatient hospitalization/prolongation of existing hospitalization,persistent/significant incapacity or substantial disruption of ability to conduct normal life functions, abnormal pregnancy outcome in child born to female patient or female partner of male patient exposed to study drug or was important medical event that jeopardized patient and required medical/surgical intervention to prevent above outcome. TEAE:AE with onset on/after start of study drug until 30 days after last dose or prior to start of subsequent anti-tumor therapy, or AE with onset before start of study drug but worsened in severity after study drug administration, or AE onset after 30 days after last dose or after start of subsequent anti-tumor therapy and treatment-related SAEs.
Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 25.25 months
Number of Patients With Best Overall Response (BOR)
BOR was defined as the best response during the anti-tumor evaluation period, which was determined using time point responses (TPRs) from date of the first dose of study drug from Cycle 1 in continuous cycle up until the last evaluable TPR prior to or on the date of PD/relapse according to the 2017 European LeukemiaNet criteria, or death; or withdrawal of consent or lost to follow-up; or receiving subsequent anti-cancer therapy, whichever was earlier. Number of patients with BOR \[complete response (CR), CR with negative minimal residual disease (CRmrd-), CR with partial hematological recovery (CRh), CR with incomplete count (CRi), morphologic leukemia-free state (MLFS), partial response (PR), stable disease (SD), and PD\] are reported.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Objective Response Rate (ORR)
ORR was defined as the percentage of patients with BOR being CRmrd-, CR, CRh, CRi, MLFS or PR. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Time to Objective Response (TTOR)
TTOR was defined as the time from the date of first study drug administration from Cycle 1 in continuous cycle to the date of first objective response (CRmrd-, CR, CRh, CRi, MLFS, or PR). CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Duration of Objective Response (DoOR)
DoOR was defined as the time from the first occurrence of objective response (CRmrd-, CR, CRh, CRi, MLFS, or PR) until PD, relapse, or death due to any cause, whichever came first. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Clinical Benefit Rate (CBR)
CBR was defined as the percentage of patients with BOR being CRmrd-, CR, CRh, CRi, MLFS, PR, or SD lasting for 3 cycles. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%. SD: Not met criteria for CR, CRi, CRmrd-, MLFS, PR, or PD.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Progression-Free Survival (PFS)
PFS was defined as the time from the start of study drug from Cycle 1 in continuous cycle to PD, or relapse, or death due to any cause, whichever occurred first. PD was defined as increase in bone marrow blast percentage and/or absolute peripheral blood blast cells: a) myeloblasts percentage increased from baseline by \>50% (if blast cells at baseline were \<30%, net increased value needs to be \>=15%) or myeloblasts percentage \>70% continued for at least 3 months; ANC was not seen to be improved by at least 100%, reached (\>0.5x10\^9/L and/or PLT reached \>50x10\^9/L, without blood transfusion); b) the absolute peripheral blood blast cell count (WBCxblast cell ratio) increased by \>50% and reached \>25x10\^9/L (without differentiation syndrome); or new extramedullary diseases.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Overall Survival (OS)
OS was defined as the time from the start of study drug from Cycle 1 in continuous cycle until the date of death due to any cause.
Time frame: From the first dose of study drug (Day 1) up to date of death due to any cause, approximately 45 months
Event-Free Survival (EFS)
EFS was defined as the time from date of first study drug administration from Cycle 1 in continuous cycle to treatment failure, relapse from CR (including CRmrd-, CR, CRh and CRi), or death due to any cause, whichever occurred first. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. Treatment failure was defined as failure to achieve CR (including CRmrd-, CR, CRh, CRi) by Week 24. Patients who did not achieve CR (including CRmrd-, CR, CRh, CRi) by Week 24 were considered to have had an event at Day 1 of first study drug administration from Cycle 1 (excluding single oral dose from PK week). For remaining CR responders (including CRmrd-, CR, CRh and CRi), event time was time of either disease relapse or death due to any cause, whichever occurred first.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Number of Patients With Post-Baseline Transfusion Independence (TI)
Post-baseline TI was defined as the absence of red blood cell and platelet transfusions for a pre-specified time during treatment period which was defined from the first dose of study drug administration from Cycle 1 in continuous cycle to 30 days after the last dose date or prior to the start of a subsequent anti-tumor therapy (whichever came first). Number of patients with post-baseline TI for \>=4 weeks and \>=8 weeks is presented.
Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 25.25 months
Plasma Concentrations of HMPL-306
Blood samples were collected at the specified timepoints to determine plasma concentrations of HMPL-306.
Time frame: PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96, 120, 144, 168 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1
Maximum Observed Plasma Concentration (Cmax) of HMPL-306
Blood samples were collected at the specified timepoints to determine Cmax of HMPL-306.
Time frame: PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96, 120, 144, 168 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1
Time to Reach the Maximum Plasma Concentration (Tmax) of HMPL-306
Blood samples were collected at the specified timepoints to determine Tmax of HMPL-306.
Time frame: PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96, 120, 144, 168 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1
Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of HMPL-306
Blood samples were collected at the specified timepoints to determine AUC0-24 of HMPL-306.
Time frame: PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1
Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)
Blood samples were collected at the specified timepoints to determine plasma concentrations of 2-HG which was a PD marker. The maximum inhibition rate for patients in different dose groups are presented.
Time frame: From PK Week Day 2 until end of treatment, approximately 24.25 months
This Phase 1, 2-part, open-label study was conducted in patients with advanced relapsed/refractory or resistant hematological malignancies that harbor isocitrate dehydrogenase mutations. The study consisted of dose escalation part (Part 1) and dose expansion part (Part 2). A total of 46 patients were enrolled in this study.
| Milestone | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 11 | 7 | 6 | 4 | 4 | 8 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 11 | 7 | 6 | 4 | 4 | 8 |
| Withdrew: Death | 1 | 3 | 7 | 5 | 5 | 3 | 2 | 4 |
| Withdrew: Sponsor terminated study | 0 | 0 | 4 | 1 | 1 | 0 | 1 | 3 |
| Withdrew: Withdrawal of consent | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
RP2D determination took the following criteria under consideration: determination of maximum tolerated dose (MTD) achieved during the dose escalation part and assessment of safety, PK and pharmacodynamics (PD).
| mg | Dose Escalation Part: Cohorts 1 to 8: HMPL-306 |
|---|---|
| Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of HMPL-306 | NA |
DLT was defined as occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless clearly unrelated to the study drug as per investigator's discretion: nonhematologic toxicity: TEAEs of Grade \>=4, Grade \>=3 with the exception of those that resolved within 72 hours (h) of onset; hematologic toxicity with the exception of neutropenia or thrombocytopenia that occurred with active leukemic disease: Grade 3 or 4 neutropenia lasting more than 7 days, Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or any requirement for platelets (PLT) transfusion, Grade 3 or greater febrile neutropenia defined as absolute neutrophil count (ANC) 1000 per cubic millimeter with a single temperature of \>38.3 degree Celsius (°C) or a sustained temperature of \>=38°C for more than 1 h; any TEAE requiring a dose delay of \>=14 days or cases of confirmed Hy's law.
| Participants | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Dose Escalation Part: Number of Patients With Dose-Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AE:unfavorable and unintended sign,symptom or disease temporally associated with use of study drug or other protocol-imposed intervention, whether or not considered related to study drug. SAE:AE that resulted in death,life-threatening AE,inpatient hospitalization/prolongation of existing hospitalization,persistent/significant incapacity or substantial disruption of ability to conduct normal life functions, abnormal pregnancy outcome in child born to female patient or female partner of male patient exposed to study drug or was important medical event that jeopardized patient and required medical/surgical intervention to prevent above outcome. TEAE:AE with onset on/after start of study drug until 30 days after last dose or prior to start of subsequent anti-tumor therapy, or AE with onset before start of study drug but worsened in severity after study drug administration, or AE onset after 30 days after last dose or after start of subsequent anti-tumor therapy and treatment-related SAEs.
| Participants | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Any TEAE | 3 | 3 | 11 | 7 | 6 | 3 | 4 | 8 |
| Any TESAE | 3 | 1 | 6 | 5 | 5 | 3 | 4 | 5 |
BOR was defined as the best response during the anti-tumor evaluation period, which was determined using time point responses (TPRs) from date of the first dose of study drug from Cycle 1 in continuous cycle up until the last evaluable TPR prior to or on the date of PD/relapse according to the 2017 European LeukemiaNet criteria, or death; or withdrawal of consent or lost to follow-up; or receiving subsequent anti-cancer therapy, whichever was earlier. Number of patients with BOR \[complete response (CR), CR with negative minimal residual disease (CRmrd-), CR with partial hematological recovery (CRh), CR with incomplete count (CRi), morphologic leukemia-free state (MLFS), partial response (PR), stable disease (SD), and PD\] are reported.
| Participants | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| CRmrd- | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| CR | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 3 |
| CRh | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| CRi | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 1 |
| MLFS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SD | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| PD | 0 | 1 | 3 | 2 | 2 | 2 | 1 | 2 |
| Not evaluable | 2 | 2 | 1 | 1 | 0 | 1 | 0 | 1 |
ORR was defined as the percentage of patients with BOR being CRmrd-, CR, CRh, CRi, MLFS or PR. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.
| percentage of patients | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 0 (NA to NA) | 0 (NA to NA) | 50.0 (18.7 to 81.3) | 40.0 (5.3 to 85.3) | 60.0 (14.7 to 94.7) | 0 (NA to NA) | 66.7 (9.4 to 99.2) | 62.5 (24.5 to 91.5) |
TTOR was defined as the time from the date of first study drug administration from Cycle 1 in continuous cycle to the date of first objective response (CRmrd-, CR, CRh, CRi, MLFS, or PR). CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.
| months | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Time to Objective Response (TTOR) | — | — | 3.680 (3.09 to 5.45) | 2.316 (0.95 to 3.68) | 4.600 (1.77 to 4.90) | — | 2.891 (2.07 to 3.71) | 1.87 (1.84 to 1.87) |
DoOR was defined as the time from the first occurrence of objective response (CRmrd-, CR, CRh, CRi, MLFS, or PR) until PD, relapse, or death due to any cause, whichever came first. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.
| months | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Duration of Objective Response (DoOR) | — | — | 5.19 (1.87 to NA) | 15.28 (7.43 to NA) | 0.84 (0.69 to NA) | — | 1.87 (NA to NA) | 3.71 (1.87 to NA) |
CBR was defined as the percentage of patients with BOR being CRmrd-, CR, CRh, CRi, MLFS, PR, or SD lasting for 3 cycles. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%. SD: Not met criteria for CR, CRi, CRmrd-, MLFS, PR, or PD.
| percentage of patients | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Clinical Benefit Rate (CBR) | 33.3 (0.8 to 90.6) | 0 (NA to NA) | 60.0 (26.2 to 87.8) | 40.0 (5.3 to 85.3) | 60.0 (14.7 to 94.7) | 25.0 (0.6 to 80.6) | 66.7 (9.4 to 99.2) | 62.5 (24.5 to 91.5) |
PFS was defined as the time from the start of study drug from Cycle 1 in continuous cycle to PD, or relapse, or death due to any cause, whichever occurred first. PD was defined as increase in bone marrow blast percentage and/or absolute peripheral blood blast cells: a) myeloblasts percentage increased from baseline by \>50% (if blast cells at baseline were \<30%, net increased value needs to be \>=15%) or myeloblasts percentage \>70% continued for at least 3 months; ANC was not seen to be improved by at least 100%, reached (\>0.5x10\^9/L and/or PLT reached \>50x10\^9/L, without blood transfusion); b) the absolute peripheral blood blast cell count (WBCxblast cell ratio) increased by \>50% and reached \>25x10\^9/L (without differentiation syndrome); or new extramedullary diseases.
| months | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) | 6.80 (NA to NA) | 3.42 (1.87 to NA) | 5.08 (0.62 to NA) | 7.39 (3.22 to NA) | 4.57 (2.10 to NA) | 3.71 (1.87 to NA) | 5.55 (0.79 to NA) | 4.62 (0.49 to NA) |
OS was defined as the time from the start of study drug from Cycle 1 in continuous cycle until the date of death due to any cause.
| months | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 6.80 (NA to NA) | 4.57 (3.42 to NA) | 13.01 (0.62 to NA) | 15.24 (5.19 to NA) | 7.66 (5.36 to NA) | 9.89 (3.06 to NA) | 6.01 (0.79 to NA) | 13.47 (0.49 to NA) |
EFS was defined as the time from date of first study drug administration from Cycle 1 in continuous cycle to treatment failure, relapse from CR (including CRmrd-, CR, CRh and CRi), or death due to any cause, whichever occurred first. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. Treatment failure was defined as failure to achieve CR (including CRmrd-, CR, CRh, CRi) by Week 24. Patients who did not achieve CR (including CRmrd-, CR, CRh, CRi) by Week 24 were considered to have had an event at Day 1 of first study drug administration from Cycle 1 (excluding single oral dose from PK week). For remaining CR responders (including CRmrd-, CR, CRh and CRi), event time was time of either disease relapse or death due to any cause, whichever occurred first.
| months | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Event-Free Survival (EFS) | 0.03 (NA to NA) | 0.03 (NA to NA) | 0.03 (0.03 to 5.65) | 0.03 (0.03 to NA) | 5.55 (0.03 to NA) | 0.03 (NA to NA) | 5.55 (0.03 to NA) | 4.62 (0.03 to NA) |
Post-baseline TI was defined as the absence of red blood cell and platelet transfusions for a pre-specified time during treatment period which was defined from the first dose of study drug administration from Cycle 1 in continuous cycle to 30 days after the last dose date or prior to the start of a subsequent anti-tumor therapy (whichever came first). Number of patients with post-baseline TI for \>=4 weeks and \>=8 weeks is presented.
| Participants | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Post-baseline TI for >=4 weeks | 3 | 3 | 7 | 4 | 4 | 4 | 3 | 8 |
| Post-baseline TI for >=8 weeks | 0 | 0 | 6 | 2 | 4 | 1 | 2 | 6 |
Blood samples were collected at the specified timepoints to determine plasma concentrations of HMPL-306.
| nanogram per milliliter (ng/mL) | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| PK Week: Pre-dose on Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| PK Week: 0.5 hour post-dose on Day 1 | 40.6 ± 33.1 | 12.8 ± 9.02 | 155 ± 200 | 40.5 ± 66.0 | 101 ± 59.6 | 28.5 ± 41.9 | 65.0 ± 80.9 | 206 ± 266 |
| PK Week: 1 hour post-dose on Day 1 | 115 ± 67.5 | 223 ± 161 | 320 ± 256 | 249 ± 278 | 541 ± 292 | 268 ± 285 | 258 ± 171 | 826 ± 545 |
| PK Week: 2 hours post-dose on Day 1 | 151 ± 80.5 | 412 ± 260 | 417 ± 140 | 535 ± 254 | 955 ± 772 | 999 ± 112 | 777 ± 559 | 869 ± 524 |
| PK Week: 3 hours post-dose on Day 1 | 130 ± 39.5 | 275 ± 103 | 379 ± 109 | 498 ± 209 | 868 ± 853 | 970 ± 229 | 689 ± 241 | 918 ± 539 |
| PK Week: 4 hours post-dose on Day 1 | 93.9 ± 8.70 | 164 ± 64.8 | 293 ± 126 | 379 ± 114 | 596 ± 525 | 744 ± 316 | 601 ± 220 | 985 ± 703 |
| PK Week: 6 hours post-dose on Day 1 | 48.9 ± 20.6 | 131 ± 26.5 | 192 ± 76.5 | 248 ± 71.5 | 327 ± 164 | 387 ± 85.8 | 498 ± 227 | 719 ± 529 |
| PK Week: 8 hours post-dose on Day 1 | 47.3 ± 21.2 | 110 ± 32.6 | 151 ± 45.6 | 204 ± 72.5 | 249 ± 191 | 331 ± 73.7 | 375 ± 111 | 517 ± 257 |
| PK Week: 24 hours post-dose on Day 1 | 23.8 ± 2.15 | 63.5 ± 27.0 | 85.6 ± 20.6 | 113 ± 21.9 | 167 ± 76.8 | 177 ± 55.6 | 183 ± 56.6 | 301 ± 148 |
| PK Week: 48 hours post-dose on Day 1 | 17.1 ± 1.00 | 42.9 ± 23.7 | 64.3 ± 14.2 | 79.2 ± 18.4 | 119 ± 49.7 | 119 ± 22.9 | 132 ± 51.9 | 202 ± 106 |
| PK Week: 72 hours post-dose on Day 1 | 15.9 ± 3.29 | 39.9 ± 15.8 | 55.9 ± 16.1 | 66.3 ± 12.8 | 97.1 ± 48.1 | 108 ± 19.9 | 114 ± 48.4 | 167 ± 76.1 |
| PK Week: 96 hours post-dose on Day 1 | 13.4 ± 1.02 | 34.2 ± 14.9 | 52.5 ± 15.0 | 61.2 ± 11.7 | 83.8 ± 38.8 | 93.0 ± 15.3 | 88.0 ± 48.8 | 175 ± 84.6 |
| PK Week: 120 hours post-dose on Day 1 | 13.3 ± 1.56 | 32.2 ± 14.6 | 43.0 ± 13.2 | 52.9 ± 4.73 | 64.0 ± 25.9 | 79.8 ± 13.1 | 83.3 ± 38.9 | 138 ± 73.4 |
| PK Week: 144 hours post-dose on Day 1 | 11.7 ± 0.424 | 29.4 ± 12.9 | 40.5 ± 14.0 | 47.2 ± 4.18 | 56.2 ± 28.1 | 72.2 ± 3.68 | 55.8 ± 26.2 | 132 ± 71.8 |
| PK Week: 168 hours post-dose on Day 1 | 9.62 ± 0.679 | 27.6 ± 20.9 | 38.9 ± 14.8 | 46.2 ± 8.64 | 90.3 ± 24.9 | 64.6 ± 8.62 | 50.7 ± 22.7 | 125 ± 68.4 |
| Cycle 2 Day 1: Pre-dose | 134 ± NA | 501 ± 244 | 765 ± 359 | 765 ± 110 | 916 ± 573 | 1558 ± 637 | 1475 ± 247 | 2133 ± 978 |
| Cycle 2 Day 1: 0.5 h post-dose | 134 ± NA | 592 ± 404 | 921 ± 458 | 871 ± 300 | 1622 ± 1510 | 1632 ± 700 | 1585 ± 318 | 2616 ± 972 |
| Cycle 2 Day 1: 1 h post-dose | 218 ± NA | 666 ± 486 | 1324 ± 611 | 1063 ± 319 | 1930 ± 1273 | 2167 ± 981 | 2250 ± 170 | 2776 ± 1066 |
| Cycle 2 Day 1: 2 h post-dose | 293 ± NA | 755 ± 267 | 1191 ± 501 | 1208 ± 363 | 1910 ± 1075 | 2310 ± 919 | 2250 ± 594 | 3372 ± 948 |
| Cycle 2 Day 1: 3 h post-dose | 282 ± NA | 738 ± 107 | 1084 ± 551 | 1227 ± 239 | 1730 ± 891 | 2213 ± 419 | 1630 ± NA | 2887 ± 1194 |
| Cycle 2 Day 1: 4 h post-dose | 253 ± 89.1 | 573 ± 26.9 | 999 ± 351 | 946 ± 125 | 1180 ± 608 | 1873 ± 597 | 1695 ± 530 | 2345 ± 775 |
| Cycle 2 Day 1: 6 h post-dose | 252 ± 114 | 505 ± 96.9 | 851 ± 298 | 870 ± 125 | 1082 ± 493 | 1697 ± 431 | 1445 ± 403 | 2242 ± 910 |
| Cycle 2 Day 1: 8 h post-dose | 276 ± 148 | 592 ± 164 | 813 ± 397 | 829 ± 27.0 | 970 ± 523 | 1770 ± 502 | 1640 ± 636 | 2170 ± 972 |
| Cycle 2 Day 1: 24 h post-dose | 206 ± 96.2 | 502 ± 160 | 837 ± 317 | 746 ± 96.8 | 899 ± 553 | 1484 ± 488 | 1230 ± NA | 2135 ± 1063 |
Blood samples were collected at the specified timepoints to determine Cmax of HMPL-306.
| ng/mL | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| PK Week Day 1 | 151 ± 33.7 | 376 ± 71.8 | 476 ± 36.6 | 574 ± 44.2 | 749 ± 76.5 | 1095 ± 13.4 | 865 ± 53.5 | 1225 ± 45.0 |
| Cycle 2 Day 1 | 413 ± 51.7 | 921 ± 30.2 | 1239 ± 61.6 | 1365 ± 21.6 | 1804 ± 70.7 | 2455 ± 31.1 | 2385 ± 16.1 | 3301 ± 31.5 |
Blood samples were collected at the specified timepoints to determine Tmax of HMPL-306.
| hour | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| PK Week Day 1 | 1.98 (0.950 to 2.92) | 1.93 (1.83 to 3.00) | 1.98 (0.933 to 3.00) | 1.92 (1.02 to 3.00) | 2.00 (1.00 to 3.00) | 3.00 (2.23 to 4.00) | 3.06 (2.10 to 6.00) | 2.09 (1.00 to 6.05) |
| Cycle 2 Day 1 | 2.38 (2.10 to 2.67) | 2.43 (1.03 to 2.98) | 1.00 (1.00 to 4.00) | 2.50 (2.00 to 3.00) | 1.50 (1.00 to 2.00) | 2.00 (1.03 to 3.00) | 1.51 (1.00 to 2.02) | 2.00 (1.92 to 2.87) |
Blood samples were collected at the specified timepoints to determine AUC0-24 of HMPL-306.
| h*ng/mL | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| PK Week Day 1 | 1143 ± 34.8 | 2625 ± 42.7 | 3780 ± 23.8 | 4811 ± 22.1 | 6436 ± 58.0 | 8368 ± 16.4 | 7846 ± 36.3 | 11211 ± 47.1 |
| Cycle 2 Day 1 | 5697 ± 52.3 | 12904 ± 24.0 | 19159 ± 53.6 | 20313 ± 8.5 | 23740 ± 66.9 | 39882 ± 34.6 | 37973 ± 30.1 | 50156 ± 43.2 |
Blood samples were collected at the specified timepoints to determine plasma concentrations of 2-HG which was a PD marker. The maximum inhibition rate for patients in different dose groups are presented.
| percentage of inhibition | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG) | 65.85 ± 24.70 | 71.49 ± 33.07 | 61.23 ± 33.67 | 82.67 ± 14.21 | 59.51 ± 61.62 | 88.54 ± 11.11 | 94.28 ± 4.82 | 87.47 ± 13.23 |
Collected over Adverse events were collected from the first dose of study drug (Day 1 of the PK week) up to 30 days after the last dose of study drug, or prior to the start of a subsequent anti-tumor therapy (whichever came first), approximately 25.25 months. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1 of the PK week) up to end of follow-up, approximately 45 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: HMPL-306 Dose Level 1 | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Cohort 2: HMPL-306 Dose Level 2 | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 3: HMPL-306 Dose Level 3 | 7/11 (63.6%) | 6/11 (54.5%) | 10/11 (90.9%) |
| Cohort 4: HMPL-306 Dose Level 4 | 5/7 (71.4%) | 5/7 (71.4%) | 7/7 (100%) |
| Cohort 5: HMPL-306 Dose Level 5 | 5/6 (83.3%) | 5/6 (83.3%) | 6/6 (100%) |
| Cohort 6: HMPL-306 Dose Level 6 | 3/4 (75%) | 3/4 (75%) | 3/4 (75%) |
| Cohort 7: HMPL-306 Dose Level 7 | 2/4 (50%) | 4/4 (100%) | 3/4 (75%) |
| Cohort 8: HMPL-306 Dose Level 8 | 4/8 (50%) | 5/8 (62.5%) | 8/8 (100%) |
| Event | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/3 | 1/3 | 3/11 | 1/7 | 2/6 | 0/4 | 2/4 | 1/8 |
| SepsisInfections and infestations | 0/3 | 1/3 | 1/11 | 1/7 | 1/6 | 2/4 | 0/4 | 0/8 |
| Septic shockInfections and infestations | 1/3 | 1/3 | 0/11 | 0/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| CellulitisInfections and infestations | 0/3 | 1/3 | 0/11 | 0/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| Escherichia bacteraemiaInfections and infestations | 0/3 | 1/3 | 0/11 | 0/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| Perirectal abscessInfections and infestations | 0/3 | 1/3 | 0/11 | 0/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| Pneumonia fungalInfections and infestations | 1/3 | 0/3 | 0/11 | 0/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 1/11 | 2/7 | 2/6 | 0/4 | 1/4 | 1/8 |
| LeukocytosisBlood and lymphatic system disorders | 0/3 | 1/3 | 0/11 | 0/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| VomitingGastrointestinal disorders | 1/3 | 0/3 | 0/11 | 0/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| Event | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 |
|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/3 | 3/3 | 1/11 | 1/7 | 2/6 | 1/4 | 1/4 | 3/8 |
| FatigueGeneral disorders | 3/3 | 1/3 | 1/11 | 0/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/3 | 1/3 | 0/11 | 1/7 | 1/6 | 0/4 | 0/4 | 0/8 |
| Increased tendency to bruiseBlood and lymphatic system disorders | 2/3 | 0/3 | 0/11 | 0/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| Oedema peripheralGeneral disorders | 1/3 | 2/3 | 1/11 | 1/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| Alanine aminotransferase increasedInvestigations | 2/3 | 0/3 | 1/11 | 1/7 | 2/6 | 1/4 | 0/4 | 0/8 |
| Aspartate aminotransferase increasedInvestigations | 2/3 | 0/3 | 1/11 | 0/7 | 2/6 | 1/4 | 0/4 | 0/8 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 1/3 | 1/11 | 1/7 | 0/6 | 0/4 | 0/4 | 1/8 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/3 | 1/3 | 1/11 | 2/7 | 0/6 | 0/4 | 0/4 | 0/8 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 2/3 | 0/11 | 0/7 | 1/6 | 0/4 | 0/4 | 0/8 |
The safety analysis set included all enrolled patients who received at least 1 dose of study drug.
| Age, Continuous(years) | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 65.7 ± 5.69 | 65.0 ± 10.15 | 72.3 ± 6.92 | 68.7 ± 5.68 | 69.2 ± 12.04 | 66.5 ± 17.71 | 67.3 ± 10.90 | 70.4 ± 13.46 | 69.2 ± 9.98 |
| Sex: Female, Male(Participants) | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 6 | 2 | 3 | 1 | 2 | 4 | 21 |
| Male | 1 | 2 | 5 | 5 | 3 | 3 | 2 | 4 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 1 | 5 | 1 | 1 | 0 | 3 | 13 |
| Not Hispanic or Latino | 3 | 1 | 8 | 2 | 5 | 3 | 4 | 5 | 31 |
| Unknown or Not Reported | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: HMPL-306 Dose Level 1 | Cohort 2: HMPL-306 Dose Level 2 | Cohort 3: HMPL-306 Dose Level 3 | Cohort 4: HMPL-306 Dose Level 4 | Cohort 5: HMPL-306 Dose Level 5 | Cohort 6: HMPL-306 Dose Level 6 | Cohort 7: HMPL-306 Dose Level 7 | Cohort 8: HMPL-306 Dose Level 8 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| White | 3 | 2 | 8 | 7 | 5 | 4 | 4 | 7 | 40 |
| Unknown or Not Reported | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Jan 2025, 45 months.
Results were first posted in Jan 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranosidenib